Jeffrey Singerman

Sure.

Good morning.

So as you said, my name is Jeff Singerman.

I am the chief operating officer slash administrator for Manhattan Endoscopy.

We are a single specialty, non-hospital affiliated ASC located in Midtown Manhattan.

We are GI specific.

We have seven procedure rooms and should probably end the year with about 10,000 patients coming through the door.

So I think part of this trend is contributed to the cost base between the hospital, the hospital OPD, and the ASC.

The cost base is much lower within the ASC environment.

And our outcomes, I'm happy to say, are probably as good if not better than what goes on in the hospital.

And then the second part that I think is contributing to this is that we can pivot from a technological standpoint

much quicker than the larger health systems that have to go through layers and layers of bureaucracy to obtain what we can do in almost a instantaneous decision.

From an administrator's standpoint or a COO's standpoint, I believe that you need to be flexible, open-minded, and evaluate what your ROI is going to be on any investment that you're going to make as this trend continues.

So I kind of divide this into two different venues.

I think one is a clinical venue and one is an administrative venue.

So from a clinical standpoint, and we've gone through two, if not three tests of AI and its current iteration, it really has not helped in the GI environment.

I think when we look out in 2030, I think where we'll probably see the most advances will be in polyp detection and possibly being able to look at when a gastroenterologist is doing histology in an area where their mucosal changes, that they conceivably determine if this is cancerous or not before it's ever removed from the body.

But where I really see in 2030, and if not sooner, the impacts on the administrative side, which would ultimately, I believe, reduce staffing and help in the area of documentation from a physician standpoint as well, that they can meet the criteria that the insurance companies are putting up there to inhibit reimbursement or look for excuses to deny claims.

Probably going to be on the EMR side.

And I see beta testing now going on in voice dictation for procedure notes, much different than what we saw in radiology in the last five to 10 years.